Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis

Journal of Medical Economics

Volumn 17, Issue 8, 2014, Pages 555-566

  Curtis, Jeffrey R ^a   Schabert, Vernon F ^b   Yeaw, Jason ^b   Korn, Jonathan R ^b   Quach, Caroleen ^c   Harrison, David J ^d   Yun, Huifeng ^a   Joseph, George J ^d   Collier, David ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b IQVIA   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d AMGEN INC   (United States)

Author keywords

Algorithm; Biologics; Claims; Cost; Effectiveness; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

ADULT; ALGORITHM; ARTICLE; BIOLOGICAL THERAPY; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA BASE; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RHEUMATOID ARTHRITIS; ADOLESCENT; ARTHRITIS, RHEUMATOID; COST; DRUG DATABASE; ECONOMICS; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; ALGORITHMS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; COSTS AND COST ANALYSIS; DATABASES, PHARMACEUTICAL; HUMANS; MIDDLE AGED; YOUNG ADULT;

EID: 84904624623     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2014.914031     Document Type: Article

References (29)

1. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84
2. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39
3. Rindfleisch JA, Muller D. Diagnosis and management of rheumatoid arthritis. Am Fam Physician 2005;72:1037-47
4. Schabert VF, Watson C, Gandra SR, et al. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. J Med Econ 2012;15:264-75
5. Bonafede MM, Gandra SR, Watson C, et al. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis. Adv Ther 2012;29:234-48
6. Estellat C, Ravaud P. Lack of head-to-head trials and fair control arms: randomized controlled trials of biologic treatment for rheumatoid arthritis. Arch Intern Med 2012;172:237-44
7. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-103
8. Weinblatt ME, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 2013;65:28-38
9. Kume K, Amano K, Yamada S, et al. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. J Rheumatol 2011;38:2169-71
10. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-19
11. Greenberg JD, Reed G, Decktor D, et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012;71:1134-42
12. Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381: 1541-50
13. Moots RJ, Haraoui B, Matucci-Cerinic M, et al. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin Exp Rheumatol 2011;29:26-34
14. Schabert VF, Bruce B, Ferrufino CF, et al. Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study. Curr Med Res Opin 2012;28:569-80
15. Bullano MF, McNeeley BJ, Yu YF, et al. Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis. Manag Care Interface 2006;19:47-53
16. Etemad L, Yu EB, Wanke LA. Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis. Manag Care Interface 2005;18:21-7
17. Gilbert Jr. TD, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2004;5:36
18. Ollendorf DA, Klingman D, Hazard E, et al. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther 2009;31:825-35
19. Carter CT, Changolkar AK, Scott McKenzie R. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients. J Med Econ 2012;15:332-9
20. Harrison DJ, Huang X, Globe D. Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis. Am J Health Syst Pharm 2010;67:1281-7
21. Tang B, Rahman M, Waters HC, et al. Treatment persistence with adalimu-mab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther 2008;30:1375-84
22. Wu E, Chen L, Birnbaum H, et al. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data. Curr Med Res Opin 2007;23:1749-59
23. Weycker D, Yu EB, Woolley JM, et al. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged4or 65 years with rheumatoid arthritis. Clin Ther 2005;27:646-56
24. Zeidler J, Mittendorf T, Muller R, et al. Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspective. Health Econ Rev 2012;2:20
25. Curtis JR, Baddley JW, Yang S, et al. Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis. Arthritis Res Ther 2011;13:R155
26. Curtis JR, Chastek B, Becker L, et al. Further evaluation of a claims-based algorithm to determine the effectiveness of biologics for rheumatoid arthritis using commercial claims data. Arthritis Res Ther 2013;15:404
27. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993;46:1075-9
28. Hamilton RJ. Tarascon Pharmacopoeia 2011 Library edn. Philadelphia, PA: Tarascon, 2011
29. Hyrich KL, Lunt M, Watson KD, et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20